AbCellera Results Presentation Deck

Q1 2021 BUSINESS UPDATE. COVID-19 PROGRAM BAMLANIVIMAB:THE MOST BROADLY USED COVID-19 ANTIBODY IN THE WORLD Since being authorized for emergency use by the US FDA in November 2020, bamlanivimab has prevented hospitalizations and death: • 400K+ patients treated • 20K+ patients kept out of hospital 11K+ lives saved ● To address emerging variants, bamlanivimab has been evaluated in clinical trials with two other antibodies, including etesevimab and VIR-7831. Ab Cellera Lilly recently transitioned to the combination of bamlanivimab and etesevimab in the US.

View entire presentation